TREATMENT OF PATIENTS WITH NONSPECIFIC INTERSTITIAL PNEUMONIA BASED ON IMMUNOLOGICAL INDICATORS

Background: Nonspecific interstitial pneumonia (NSIP) is a heterogeneous interstitial lung disease characterized by varying degrees of interstitial inflammation and fibrosis. Clinical presentation, functional impairment and treatment response differ between patients. Immunological indicators may provide additional information about inflammatory activity and help characterize disease phenotypes, although they should not replace clinical, radiological and histopathological assessment. Objective: To evaluate selected circulating immunological indicators in patients with NSIP and to assess their potential value in monitoring response to treatment, including an exploratory comparison of standard therapy with standard therapy supplemented by Longidaza (bovhyaluronidase azoximer). Materials and methods: The study included 48 patients with NSIP and a healthy control group of 25 individuals. A comparison group comprising patients with other respiratory diseases was also included; its size and diagnostic composition should be specified in the final manuscript. Clinical assessment was complemented by pulmonary function testing, the six-minute walk test and the St George's Respiratory Questionnaire (SGRQ). Serum concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10) and tumour necrosis factor-alpha (TNF-α) were evaluated. Patients received standard treatment according to their clinical condition; in an exploratory treatment subgroup, Longidaza was added to standard therapy. The exact treatment allocation, doses, duration, assay methods and statistical procedures should be reported in the final version. Results: The study design enables assessment of the relationship between systemic cytokine profiles, respiratory functional impairment, exercise capacity and health-related quality of life. Numerical baseline and post-treatment cytokine concentrations, between-group comparisons and treatment-effect estimates must be inserted from the verified study dataset before submission. No quantitative treatment effect is stated in this draft. Conclusion: Measurement of IL-6, IL-10 and TNF-α may complement clinical and functional assessment in NSIP and may be useful for describing inflammatory activity and monitoring changes over time. At present, cytokine levels should be interpreted as adjunctive biomarkers rather than stand-alone criteria for selecting immunosuppressive treatment. The clinical value of adding Longidaza requires confirmation using clearly defined treatment groups and adequately powered comparative analyses.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24359169
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TREATMENT OF PATIENTS WITH NONSPECIFIC INTERSTITIAL PNEUMONIA BASED ON IMMUNOLOGICAL INDICATORS

Zakiryayeva Parvina Odilovna
Zenodo (CERN European Organization for Nuclear Research)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

TREATMENT OF PATIENTS WITH NONSPECIFIC INTERSTITIAL PNEUMONIA BASED ON IMMUNOLOGICAL INDICATORS

Zakiryayeva Parvina Odilovna
article en

Abstract

Background: Nonspecific interstitial pneumonia (NSIP) is a heterogeneous interstitial lung disease characterized by varying degrees of interstitial inflammation and fibrosis. Clinical presentation, functional impairment and treatment response differ between patients. Immunological indicators may provide additional information about inflammatory activity and help characterize disease phenotypes, although they should not replace clinical, radiological and histopathological assessment. Objective: To evaluate selected circulating immunological indicators in patients with NSIP and to assess their potential value in monitoring response to treatment, including an exploratory comparison of standard therapy with standard therapy supplemented by Longidaza (bovhyaluronidase azoximer). Materials and methods: The study included 48 patients with NSIP and a healthy control group of 25 individuals. A comparison group comprising patients with other respiratory diseases was also included; its size and diagnostic composition should be specified in the final manuscript. Clinical assessment was complemented by pulmonary function testing, the six-minute walk test and the St George's Respiratory Questionnaire (SGRQ). Serum concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10) and tumour necrosis factor-alpha (TNF-α) were evaluated. Patients received standard treatment according to their clinical condition; in an exploratory treatment subgroup, Longidaza was added to standard therapy. The exact treatment allocation, doses, duration, assay methods and statistical procedures should be reported in the final version. Results: The study design enables assessment of the relationship between systemic cytokine profiles, respiratory functional impairment, exercise capacity and health-related quality of life. Numerical baseline and post-treatment cytokine concentrations, between-group comparisons and treatment-effect estimates must be inserted from the verified study dataset before submission. No quantitative treatment effect is stated in this draft. Conclusion: Measurement of IL-6, IL-10 and TNF-α may complement clinical and functional assessment in NSIP and may be useful for describing inflammatory activity and monitoring changes over time. At present, cytokine levels should be interpreted as adjunctive biomarkers rather than stand-alone criteria for selecting immunosuppressive treatment. The clinical value of adding Longidaza requires confirmation using clearly defined treatment groups and adequately powered comparative analyses.

Zenodo (CERN European Organization for Nuclear Research)
Samarkand State Medical Institute (UZ)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon